Application of pentacyclic triterpene structure modified compound in preparation of vitiligo medicine and novel preparation

By modifying the pentacyclic triterpenoid compound CKBA to inhibit CD8+ T cell differentiation, a topical drug composition was developed, which solved the problems of poor targeting and large side effects in existing vitiligo treatments, and achieved safe and effective vitiligo treatment.

CN118924766APending Publication Date: 2024-11-12SUZHOU BOTANY BIOMEDICALS
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202311448294.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-10
Filing Date
2023-11-02
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing vitiligo treatments have poor targeting, easily leading to serious adverse reactions and side effects, and there is a lack of effective new drug solutions.

Method used

By using pentacyclic triterpenoid modified compounds, especially 3-o-α-cyclohexanoyl-11-keto-β-boswellic acid (CKBA), topical pharmaceutical compositions such as ointments were developed to treat vitiligo by inhibiting the differentiation of CD8+ T cells into Tc1 and Tc17 subsets. These ointments contain excipients such as white petrolatum, light liquid paraffin, and isopropyl myristate.

Benefits of technology

It significantly inhibits the differentiation of CD8+ T cells, reduces the production of IFN-γ and IL-17A, improves the vitiligo phenotype, reduces skin CD8+ T cell infiltration, and provides a safe and effective treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004529568990000031
    Figure BDA0004529568990000031
  • Figure BDA0004529568990000041
    Figure BDA0004529568990000041
  • Figure BDA0004529568990000081
    Figure BDA0004529568990000081
Patent Text Reader

Abstract

The invention provides an application of a pentacyclic triterpene structure modified compound in preparation of a vitiligo medicine and a novel preparation. The pentacyclic triterpene structure modified compound disclosed by the invention can be used for effectively treating leucoderma. The pentacyclic triterpene structure modified compound can also be used for inhibiting differentiation of CD8 < + > T cells, especially inhibiting differentiation of the CD8 < + > T cells into a Tc1 cell subset and / or a Tc17 cell subset. The invention provides a new way for relieving and treating vitiligo, and also provides a new way for differentiation regulation of CD8 + T cells to different subgroups. The invention also optimizes the preparation of the pentacyclic triterpenoid structure modified compound, provides an ointment preparation with excellent effect, and comprises a series of auxiliary agents which can assist the pentacyclic triterpenoid structure modified compound to be better absorbed by the skin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medicine, and more specifically, the present invention relates to the application of pentacyclic triterpene structure-modified compounds in the preparation of vitiligo drugs and new preparations. Background Art

[0002] Vitiligo, commonly known as "white spots" and "white spots", is a common acquired localized or generalized skin disease with depigmented spots of varying sizes and numbers as typical skin lesions, generally without subjective symptoms.

[0003] The incidence of vitiligo in the world's population is 0.5% to 1%. It is reported that the incidence of vitiligo varies depending on race, geographical environment and population (Ezzedine K, et al., 2015, 386(9988):74-84). Currently, the prevalence of vitiligo shows an increasing trend year by year.

[0004] According to the Vitiligo Global Issue Consensus Conference and the current mainstream views at home and abroad, China's "Vitiligo Diagnosis and Treatment Consensus (2018 Edition)" divides vitiligo into four types: common type, segmental type, mixed type and undetermined type. The "vitiligo" usually refers to common vitiligo (Vitiligo vulgaris), also known as non-segmental vitiligo (NSV) (Meredith F, et al., 2013, 170 (3): 565-70).

[0005] Vitiligo is divided into progressive stage and stable stage according to whether the condition progresses: the condition of patients in progressive stage progresses, and the area of ​​white spots tends to expand in the near future; the condition of patients in stable stage is stable, and the area of ​​white spots shrinks or remains unchanged.

[0006] The pathogenesis of vitiligo is still unknown, and it is stubborn and difficult to treat, with repeated attacks. Although it does not affect physical health, it imposes a huge psychological burden on patients, seriously affecting their quality of life and easily causing a variety of psychological symptoms or diseases. Therefore, vitiligo is one of the important research topics in the field of skin diseases in the world.

[0007] Although vitiligo is considered to be related to immunity, it is a particularly special disease with a special pathogenesis and special symptoms. Although it will be reflected in changes on the skin surface, it is completely different from psoriasis. Some theories believe that when the immune function is disordered, the immune system will attack melanocytes, leading to cell apoptosis, decreased tyrosinase activity and reduced melanin content, resulting in white spots, but the mechanism is still unclear. Genome-wide association studies (GWAS) and functional pathway analysis found (SHEN C, et al., 2016, 7: 3) that most vitiligo susceptibility sites encode immune regulatory proteins or melanocyte components that mediate immune targeting.

[0008] So far, there are no new drugs for vitiligo worldwide, and several JAK-STAT inhibitors are in clinical trials. According to the Vitiligo Research Foundation's 2021 New Drug Progress Report (Vitiligo Drug Pipeline Analysis and Market Insights—UPDATE), as of 2018, the global vitiligo treatment market was $143.8 million, and it is expected to reach $144.5 million by 2026, with a compound annual growth rate of 5.8%. The largest market share (54.7%) is topical drugs, the second largest share is phototherapy, followed by surgical methods and others. The dynamics of the vitiligo market are expected to change rapidly in the next 3 to 7 years, because it may take a long time (ten years) to develop new vitiligo drugs from scratch, but using drugs that have been approved to treat other diseases, such as JAK inhibitors, can launch drugs the fastest, but the production cost is high and the price is expensive.

[0009] Currently, the main topical drugs used in clinical treatment of vitiligo include glucocorticoids, calcium phosphate inhibitors, etc. In fact, they are not very effective against vitiligo and have poor targeting, which can easily lead to serious adverse reactions and side effects.

[0010] Therefore, the field is in urgent need of finding new drugs for treating vitiligo, in order to change the current situation that vitiligo has no cure or the treatment effect is unsatisfactory. Summary of the invention

[0011] The purpose of the present invention is to provide the use of pentacyclic triterpene structure-modified compounds in the preparation of vitiligo drugs and new preparations.

[0012] The present invention also aims to provide a new use of a pentacyclic triterpene structure-modified compound, which is to inhibit CD8 + Differentiation of T cells; in particular, inhibiting their differentiation into Tc1 subset and / or Tc17 subset.

[0013] In the first aspect of the present invention, there is provided the use of a compound represented by formula (I) or its isomers, solvates or precursors, or pharmaceutically acceptable salts thereof, for preparing a pharmaceutical composition for alleviating or treating vitiligo;

[0014]

[0015] Wherein, R is independently selected from: hydrogen, hydroxyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halogen.

[0016] In one or more embodiments, the pharmaceutical composition containing the compound of formula (I) is an external dosage form.

[0017] In one or more embodiments, the pharmaceutical composition containing the compound of formula (I) is selected from: ointments (such as creams, pastes), gels, foams, sprays, powders, and creams.

[0018] In one or more embodiments, the pharmaceutical composition is an ointment preparation, comprising: a compound represented by formula (I); and:

[0019] The auxiliary agent 1 is selected from one or more of white vaseline, paraffin, lanolin, microcrystalline wax, beeswax, spermaceti, ozokerite, glyceryl stearate, stearic acid or cholesterol; preferably, the paraffin is light liquid paraffin; preferably, the auxiliary agent 1 is white vaseline and light liquid paraffin;

[0020] Auxiliary agent 2 is selected from: one or more of isopropyl myristate, azone or N-methylpyrrolidone; preferably, the auxiliary agent 2 is isopropyl myristate;

[0021] The auxiliary agent 3 is selected from one or more of vitamin E, butylated hydroxytoluene, butylated hydroxyanisole, tocopherol, propyl gallate or tert-butylhydroquinone; preferably, the auxiliary agent 3 is vitamin E.

[0022] In one or more embodiments, the vitiligo is: CD8 + Vitiligo is caused by the differentiation of T cells into Tc1 cell subsets (effector cells that produce IFN-γ).

[0023] In one or more embodiments, the vitiligo is: CD8 + Vitiligo is caused by T cell differentiation into Tc17 cell subsets (effector cells that produce IL-17A).

[0024] In one or more embodiments, the compound represented by formula (I) has a structure represented by formula (II).

[0025]

[0026] The English name of the compound of formula (II) is 3-o-α-cyclohexanoyl-11-keto-β-boswellic acid, abbreviated as CKBA.

[0027] In another aspect of the present invention, a pharmaceutical composition for alleviating or treating vitiligo comprises: a compound represented by formula (I); and:

[0028] The auxiliary agent 1 is selected from one or more of white vaseline, paraffin, lanolin, microcrystalline wax, beeswax, spermaceti, ozokerite, glyceryl stearate, stearic acid or cholesterol; preferably, the paraffin is light liquid paraffin; preferably, the auxiliary agent 1 is white vaseline and light liquid paraffin;

[0029] Auxiliary agent 2 is selected from: one or more of isopropyl myristate, azone or N-methylpyrrolidone; preferably, the auxiliary agent 2 is isopropyl myristate; and

[0030] The auxiliary agent 3 is selected from one or more of vitamin E, butylated hydroxytoluene, butylated hydroxyanisole, tocopherol, propyl gallate or tert-butylhydroquinone; preferably, the auxiliary agent 3 is vitamin E.

[0031] In one or more embodiments, the pharmaceutical composition comprises: a compound represented by formula (I), white vaseline, light liquid paraffin, isopropyl myristate and vitamin E, and comprises, by weight: the compound represented by formula (I): 25 to 250, preferably 50 to 200, such as 65, 75, 90, 120, 150 or 180 parts by weight; white vaseline: 9000 to 18000, preferably 10000 to 16500, such as 12000, 13347, 13422 or 15000 parts by weight; light liquid paraffin: 400-1200, preferably 550-1000, such as 600, 650, 750, 800 or 900 parts by weight; isopropyl myristate: 400-1200, preferably 550-1000, such as 600, 650, 750, 800 or 900 parts by weight; vitamin E: 1.5-5, preferably 2-4.5, such as 2.5, 3, 4 parts by weight.

[0032] In another aspect of the present invention, there is provided a use of a compound represented by formula (I) or an isomer, solvate or precursor thereof, or a pharmaceutically acceptable salt thereof, for preparing a method for inhibiting CD8 + Compositions for T cell differentiation (such as cell culture media or pharmaceutical compositions);

[0033] In one or more embodiments, the inhibition of CD8 + T cells differentiate into:

[0034] Inhibition of CD8+ Differentiation of T cells into Tc1; and / or

[0035] Inhibition of CD8 + Differentiation of T cells into Tc17.

[0036] In one or more embodiments, the compound of formula (I) is prepared by the following method: using 11-carbonyl-β-acetyl boswellic acid as a raw material, replacing its AcO- group with Group.

[0037] In one or more embodiments, the compound of formula (I) is prepared by the following method:

[0038] (i) using 11-carbonyl-β-acetylboswellic acid as a raw material and reacting it with a base to obtain 11-carbonyl-β-boswellic acid; and

[0039] (ii) reacting 11-carbonyl-β-boswellic acid with cyclohexanecarbonyl chloride to obtain a compound represented by formula (I).

[0040] In one or more embodiments, the compound represented by formula (I) or its isomer, solvate or precursor, or their pharmaceutically acceptable salts are used as the main active ingredient (active component) in the composition (including pharmaceutical composition).

[0041] In one or more embodiments, the compound represented by formula (I) or its isomer, solvate or precursor, or their pharmaceutically acceptable salts is used as the only active ingredient (active component) in the composition (including pharmaceutical composition).

[0042] In one or more embodiments, the compound represented by formula (I) or its isomers, solvates or precursors, or pharmaceutically acceptable salts thereof can be used in combination with other active ingredients, each exerting an independent effect.

[0043] In one or more embodiments, the compound represented by formula (I) or its isomer, solvate or precursor, or their pharmaceutically acceptable salts can be used in combination with the adjuvant (preferably white vaseline, light liquid paraffin, isopropyl myristate and vitamin E) to exert a synergistic effect.

[0044] In another aspect of the present invention, a method for inhibiting CD8 + A method for differentiating CD8 T cells, comprising: treating CD8 T cells with a compound represented by formula (I) or its isomer, solvate or precursor, or a pharmaceutically acceptable salt thereof; + T cells, thereby inhibiting CD8 + Differentiation of T cells.

[0045] In one or more embodiments, the inhibition of CD8+ T cell differentiation: suppressor CD8 + T cells differentiate into the Tc1 subset (which suppresses the production of IFN-γ-producing effector cells).

[0046] In one or more embodiments, inhibition of CD8 + T cells differentiate into the Tc17 subset (which inhibits the generation of IL-17A-producing effector cells).

[0047] In one or more embodiments, the compound represented by formula (I) or its isomer, solvate or precursor, or a pharmaceutically acceptable salt thereof is in CD8 + The concentration in T cell culture is 1-100 uM; preferably 2-80 uM (such as 3, 4, 5, 6, 8, 10, 12, 15, 20, 30, 40, 50, 60 or 70 uM, etc.).

[0048] In one or more embodiments, the method maintains CD8 + T cells are in an undifferentiated state.

[0049] In one or more embodiments, the method maintains CD8 + T cells are in the naive CD8 + T cells.

[0050] In one or more embodiments, the inhibition of CD8 + The T cell method is an in vitro method.

[0051] In one or more embodiments, the inhibition of CD8 + T cell method is to inhibit CD8 + T cell culture / cell population (eg, enriched cell population or passaged cell population).

[0052] In one or more embodiments, the inhibition of CD8 + The T cell method is a method that does not directly aim at treating a disease (a non-therapeutic method).

[0053] In another aspect of the present invention, a method for alleviating or treating vitiligo is provided, the method comprising: administering an effective amount of the pharmaceutical composition of the present invention to a subject in need of treatment.

[0054] Other aspects of the present invention will be apparent to those skilled in the art in view of the disclosure herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1A , Figure 1B and Figure 1C CKBA compounds reduce CD8+ Induces T cell differentiation efficiency towards Tc1 and inhibits IFN-γ production.

[0056] Figure 2A , Figure 2B and Figure 2C CKBA compounds reduce CD8 + Induces T cell differentiation efficiency towards Tc17 and inhibits IL-17A production.

[0057] Figure 3 CKBA ointment was used to treat vitiligo animal models, effectively improving the vitiligo phenotype (the degree of hair whitening) of the animals, with blank ointment as a control.

[0058] Figure 4 : CKBA ointment treats vitiligo animal models, resulting in CD8 infiltration in the animal skin + The infiltration of T cells was significantly reduced. DETAILED DESCRIPTION

[0059] After in-depth research, the inventors have revealed for the first time that a pentacyclic triterpene structure-modified compound can effectively treat vitiligo. In order to improve the efficacy, the present invention also optimizes the preparation of the pentacyclic triterpene structure-modified compound, and provides an excellent ointment preparation containing a series of adjuvants, which can help the pentacyclic triterpene structure-modified compound to be better absorbed by the skin. The pentacyclic triterpene structure-modified compound can also be used to inhibit CD8 + The invention is completed on the basis of the above.

[0060] the term

[0061] The term "alkyl" as used herein refers to a straight or branched saturated aliphatic hydrocarbon group containing 1 to 4 carbon atoms (preferably 1 to 2 carbon atoms). For example, alkyl includes but is not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and tert-butyl.

[0062] As used herein, the term "alkenyl" includes straight and branched chain hydrocarbon groups containing at least one carbon-carbon double bond and 2 to 4 carbon atoms, preferably 2 to 3 carbon atoms.

[0063] As used herein, the term "alkynyl" includes straight and branched chain hydrocarbon groups containing at least one carbon-carbon triple bond and 2 to 4 carbon atoms, preferably 2 to 3 carbon atoms.

[0064] The term "halogen" as used herein refers to F, Cl, Br, or I.

[0065] The term "isomer" as used herein includes geometric isomers, enantiomers, diastereomers (eg, cis-trans isomers, conformational isomers).

[0066] The ones used in this article The representation method of is well known to those skilled in the art, which indicates that the group R can be substituted at any one or more substitutable positions on the ring. Moreover, the selection of R can be different at different substitution positions.

[0067] The term "solvate" used herein refers to a compound that carries solvent molecules, for example, the solvate may be a hydrate.

[0068] In the present invention, the term "comprising" means that various components can be used together in the mixture or composition of the present invention. Therefore, the terms "consisting mainly of" and "consisting of" are included in the term "comprising".

[0069] In the present invention, "pharmaceutically acceptable" ingredients are substances that are suitable for use in humans and / or animals without excessive adverse side effects (such as toxicity, irritation and allergic reactions), that is, substances with a reasonable benefit / risk ratio.

[0070] In the present invention, the pharmaceutical composition may further include a "pharmaceutically acceptable carrier", which is a pharmaceutically or food-acceptable solvent, suspending agent or excipient for delivering the compound of formula (I), isomer, solvate, precursor, or pharmaceutically acceptable salt thereof to animals or humans. The carrier may be a liquid or a solid.

[0071] In the present invention, unless otherwise specified, the "medium" is suitable for CD8 + T cell growth medium, in which factors can be added to make CD8 + T cells differentiate (simulating CD8 + T cell differentiation process). For example, adding anti-CD3, anti-CD28, IL-2 and IL-12 causes the cells to differentiate into effector cells that produce IFN-γ, referred to as Tc1 cells. For example, adding anti-CD3, anti-CD28, TGF-β, IL-6, IL-23, IL-1β and anti-IFN-γ causes the cells to differentiate into effector cells that produce IL-17A, referred to as Tc17 cells (this simulates the CD8 in vivo environment). + T cells differentiate into Tc17).

[0072] As used in the present invention, the "CD8 +"Vitiligo caused by T cell differentiation into Tc1 cell subsets (effector cells that produce IFN-γ)" refers to a type of vitiligo, the occurrence of which is mainly caused by excessive production of IFN-γ.

[0073] As used in the present invention, the "CD8 + "Vitiligo caused by T cell differentiation into Tc17 cell subsets (effector cells that produce IL-17A)" refers to a type of vitiligo, the occurrence of which is mainly caused by excessive production of IL-17A.

[0074] Compound

[0075] In the present invention, a compound as shown in structural formula (I) is first provided:

[0076]

[0077] Wherein, R is independently selected from: hydrogen, hydroxyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halogen. Preferably, R is independently selected from: hydrogen, hydroxyl, C1-C2 alkyl.

[0078] The present invention also includes isomers, solvates, precursors, or pharmaceutically acceptable salts thereof of the above-mentioned compound of formula (I), as long as they also have the same or substantially the same functions as the compound of formula (I). The "pharmaceutically acceptable salt" refers to a salt formed by the reaction of a compound with an inorganic acid, an organic acid, an alkali metal or an alkaline earth metal. These salts include (but are not limited to): (1) salts formed with the following inorganic acids: such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid; (2) salts formed with the following organic acids, such as acetic acid, oxalic acid, succinic acid, tartaric acid, methanesulfonic acid, maleic acid, or arginine. Other salts include salts formed with alkali metals or alkaline earth metals (such as sodium, potassium, calcium or magnesium) in the form of esters, carbamates, or other conventional "prodrugs". The compound has one or more asymmetric centers. Therefore, these compounds may exist as racemic mixtures, individual enantiomers, individual diastereomers, diastereoisomer mixtures, cis or trans isomers.

[0079] The "precursor of a compound" refers to a compound of formula (I), or a salt or solution of a compound of formula (I) which undergoes metabolism or chemical reaction in the patient's body after being taken by an appropriate method.

[0080] As a preferred embodiment of the present invention, the compound has a structure shown in formula (II).

[0081]

[0082] The English name of the compound of formula (II) is 3-o-α-cyclohexanoyl-11-keto-β-boswellic acid, abbreviated as CKBA. Its molecular formula is 37 H 56 O5, molecular weight 581.

[0083] Those skilled in the art should understand that, after knowing the structure of the compound of the present invention, the compound of the present invention can be obtained by a variety of methods well known in the art, using known raw materials, such as chemical synthesis or extraction from organisms (such as animals or plants), and these methods are all included in the present invention.

[0084] For example, as a method for preparing the compound represented by formula (I) of the present invention, the method comprises: using 11-carbonyl-β-acetyl boswellic acid as a raw material, replacing the AcO- group thereof with Group. More preferably, the preparation steps include: (i) using 11-carbonyl-β-acetyl boswellic acid (AKBA) as a raw material, reacting with a base (such as KOH) to obtain 11-carbonyl-β-boswellic acid; and (ii) reacting 11-carbonyl-β-boswellic acid with cyclohexanecarbonyl chloride to obtain the compound shown in formula (I). Other methods for preparing the compound of formula (I) are also included in the present invention, for example, using 11-carbonyl-β-boswellic acid (KBA) as a raw material, reacting it with cyclohexanecarbonyl chloride to directly obtain the compound shown in formula (I).

[0085] The synthesized compound can be further purified by column chromatography, high performance liquid chromatography, etc. In addition, it can also be further purified by crystallization. It should be understood that a variety of purification methods can be applied to the present invention.

[0086] Uses: Relieve or treat vitiligo

[0087] The full name of 11-carboxyl-β-acetyl boswellic acid is acetyl-11-keto-β-boswellic acid, referred to as AKBA, which is one of the important components contained in the gum resin of the plant Boswellia caryophyllus. Boswellia extract has been used as an anti-inflammatory agent in traditional medicine, such as for the treatment of arthritis and ulcerative colitis. In addition, boswellic acid has attracted attention due to its anti-proliferative effect. Boswellic acid can inhibit the growth and apoptosis of several leukemia cell lines and melanoma in vitro. Studies on boswellic acid have shown that 11-carboxyl-β-acetyl boswellic acid shows the most significant 5-LOX inhibitory activity (British J Pharmacology, 1996, 117, 615-618).

[0088] In previous work, the inventors obtained a new compound 3-o-α-cyclohexanoyl-11-keto-β-boswellic acid, referred to as CKBA, by chemical modification of AKBA. Compared with AKBA, CKBA can more significantly inhibit cell division and proliferation, and at the same time, has a more significant therapeutic effect in a mouse psoriasis model. However, in previous work, it is still unclear whether AKBA or CKBA is effective for vitiligo, which has a very different mechanism from psoriasis.

[0089] In the present invention, it is firstly disclosed that the compound represented by the structural formula (I) has the function of relieving or treating vitiligo, and the technical effect is excellent. Vitiligo is a special disease, which has extremely significant differences in pathogenesis and symptoms from other types of skin diseases such as psoriasis.

[0090] Through studies at the cellular level and animal disease model studies, the inventors have demonstrated that CKBA has significant uses in treating vitiligo.

[0091] Based on the new discovery of the inventors, the present invention discloses a new use of a pentacyclic triterpene structure modified compound. The preferred compound of the present invention is a compound with stronger biological activity obtained by chemically modifying acetyl-11-keto-β-boswellic acid (AKBA): 3-o-α-cyclohexanoyl-11-keto-β-boswellic acid, i.e., CKBA. In vivo experiments can effectively improve the "vitiligo" phenotype of mice. It can be used to prepare drugs for treating and / or preventing vitiligo.

[0092] The present invention discloses a new medical use of a CKBA compound or an analog thereof (i.e., a compound of formula (I) of the present invention or an isomer, solvate or precursor thereof, or a pharmaceutically acceptable salt thereof), namely, use thereof in the preparation of a drug for treating and / or preventing vitiligo. Furthermore, the present invention also includes a drug for treating vitiligo, wherein the active ingredient is CKBA or an analog thereof.

[0093] The CKBA compound or its analogues of the present invention are prepared in a conventional pharmaceutical method with pharmaceutically acceptable excipients to form an external dosage form. In a preferred embodiment, the weight content of the CKBA compound or its derivatives can be 0.01%-1.5%. It should be understood that the physician can also make appropriate dosage changes according to the actual clinical situation.

[0094] The present invention also provides a method for alleviating or treating vitiligo, comprising: administering an effective amount of the compound represented by formula (I) or its isomers, solvates or precursors, or pharmaceutically acceptable salts thereof to a subject in need of treatment.

[0095] Purpose: Regulate CD8 + Differentiation of T cells

[0096] In cytotoxic T lymphocytes (CTL), CD8 + T cells belong to a subpopulation that expresses CD8 on their surface. CD8 is a dimeric co-receptor that allows CD8 + T cells recognize peptides presented by MHC class I proteins.

[0097] Naive CD8 differentiated into effector or memory cell types + T cells play a specific role in mediating adaptive immune responses. + T cells can differentiate into a variety of subsets, each with significantly different functions and roles. + T cell subtypes include Tc1, Tc2, Tc9, Tc17, Tc22, etc.

[0098] The inventors found that CKBA can effectively reduce CD8 + In vitro differentiation efficiency of T cells into Tc1 and Tc17, reduced production of IFN-γ and IL-17A.

[0099] CD8 + T cells can mediate the killing of melanocytes. CD8 + The content of T cells increased significantly, and the severity of the disease and the ability to kill melanocytes were significantly higher than those of CD8 + The number of T cells was positively correlated. At the same time, the expression levels of serum interferon-γ (IFN-γ) and interleukin 17A (IL-17A) increased significantly. + T cells are an important target.

[0100] Aiming at the pathogenesis of vitiligo, the present invention adopts relevant pharmacological experimental methods to conduct in vivo and in vitro efficacy experiments on CKBA compounds for the treatment of vitiligo. + T cell division and proliferation, in vitro induced differentiation efficiency, cytokine production capacity, degree of re-pigmentation of depigmented skin, skin CD8 + The efficacy of CKBA compounds in the treatment of vitiligo was studied by conducting pharmacodynamic studies on T cell infiltration and other aspects.

[0101] In the embodiments of the present invention, the experiments show that the use of CKBA compounds can effectively reduce the naive CD8 +In vitro induction and differentiation efficiency of T cells, inhibiting the production of IFN-γ and IL-17A; can help the skin or hair of vitiligo mouse models to recolor, and reduce the number of CD8 + Infiltration of T cells improves the vitiligo-like phenotype in mice.

[0102] Based on the new discovery of the inventors, the present invention also provides the use of the compound represented by formula (I) or its isomers, solvates or precursors, or pharmaceutically acceptable salts thereof, for preparing a method for inhibiting CD8 + The composition can be a cell culture medium or a pharmaceutical composition. + T cell differentiation: suppressor CD8 + T cell differentiation into the Tc1 subset (suppressing the generation of IFN-γ-producing effector cells); and / or suppressing CD8 + T cells differentiate into the Tc17 subset (suppresses the production of IL-17A-producing effector cells.

[0103] Once stimulated by cytokines such as IL-2 and IL-12, the Tc1 cell subset has the ability to kill target cells directly or indirectly. In addition, cytotoxic Tc1 cells can release IFN-γ or TNF-α to further regulate the host's immune response. Tc2 T cells regulate effector and auxiliary immune responses by secreting cytokines IL-4, IL-5, IL-10, and IL-13. Although Tc2 cells have the ability to perform cytotoxic functions, this T cell subset is generally not as effective as its Tc1 counterpart during infection.

[0104] The Tc17 cell subset is a cell population different from the Tc1 subset. It is a CD8+ effector cell that secretes IL-17+. It is a new cell subset that is independent in both cell function and differentiation. Tc17 cells have a completely different cell phenotype from other cytotoxic T cells, which rarely or do not secrete IFN-γ and IL-4. Compared with Tc1 and Tc2, Tc17 neither expresses granzyme B nor perforin, and has no cell killing activity against antigen-bound targets. Compared with Th17 cells, Tc17 cells are significantly different. Tc17 has been shown to work under a variety of conditions, and Tc17 is accompanied by a higher proportion of neutrophils in the lungs compared to animals injected with Tc1. Tc17 has also been shown to participate in immune effects in some diseases, thereby regulating the condition. Therefore, it is necessary to develop methods for regulating Tc17.

[0105] The present invention discloses for the first time that the compound represented by formula (I) or its isomers, solvates or precursors, or their pharmaceutically acceptable salts have the effect of regulating CD8 +The ability of T cells to differentiate into Tc1 or Tc17 subsets provides an effective way to regulate the differentiation of such cell subsets.

[0106] Composition

[0107] The dosage form of the pharmaceutical composition of the present invention can be varied, as long as it can effectively deliver the active ingredient to the mammalian body. For example, it can be selected from: gel, aerosol, tablet, capsule, powder, granule, syrup, solution, or suspension. According to the type of disease treated by the compound of the present invention, those skilled in the art can select a dosage form that is convenient for use.

[0108] From the standpoint of ease of preparation and administration, the preferred pharmaceutical composition is a solid or semi-solid composition. The compound of the present invention or its pharmaceutical composition can also be stored in a sterile device suitable for injection or instillation.

[0109] When used to alleviate or treat vitiligo, it is preferred that the pharmaceutical composition is administered in an external manner. Various pharmaceutical carriers suitable for preparing external dosage forms can be applied to the present invention. As a preferred embodiment of the present invention, the pharmaceutical composition containing the compound shown in the formula (I) is an external dosage form, including (but not limited to) selected from: ointment (such as cream, paste), gel, foam, spray, powder, cream.

[0110] As a preferred embodiment of the present invention, a pharmaceutical composition for treating vitiligo is provided, comprising: (a) an effective amount of a compound described in formula (I), or an isomer, solvate, precursor, or pharmaceutically acceptable salt thereof; and (b) an adjuvant. The adjuvant is suitable and can synergize and enhance the therapeutic effect of the compound described in formula (I). The adjuvant includes: adjuvant 1, selected from: one or more of white vaseline, paraffin, lanolin, microcrystalline wax, beeswax, spermaceti, ceresin, stearyl glyceride, stearic acid or cholesterol; adjuvant 2, selected from: one or more of isopropyl myristate, azone or N-methylpyrrolidone; adjuvant 3, selected from: one or more of vitamin E, butylated hydroxytoluene, butylated hydroxyanisole, tocopherol, propyl gallate or tert-butylhydroquinone.

[0111] Most preferably, the adjuvants include: white vaseline, light liquid paraffin, isopropyl myristate and vitamin E.

[0112] The effective dosage of the compound of formula (I) as an active ingredient may vary with the mode of administration and the severity of the disease to be treated. For example, the compound of the present invention may be administered at a dosage of about 0.0001-500 mg / kg, preferably 0.001-300 mg / kg, more preferably 0.01-200 mg / kg of animal body weight per day, to obtain satisfactory results, preferably in 1-3 divided doses per day, or in a sustained release form. This dosage regimen may be adjusted to provide the best therapeutic response. For example, several divided doses may be administered per day, or the dosage may be reduced proportionally, depending on the urgency of the treatment condition.

[0113] In addition, the compound of formula (I), or its isomer, solvate, precursor, or pharmaceutically acceptable salt thereof can also be added to an appropriate culture medium for regulating the differentiation of CD8+T cells. In some preferred embodiments, the concentration of the compound in the culture medium is 1 to 100 uM; preferably 2 to 80 uM. The amount of addition can be adjusted according to actual conditions.

[0114] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer.

[0115] Example 1: CKBA compounds inhibit CD8 in vitro + Experiment on inducing differentiation of T cells into Tc1

[0116] 8-10 week old C57BL / 6 mice were selected and red blood cells were lysed with red blood cell lysis buffer to obtain spleen single cell suspension. + Naive CD8 + T cells. 1.0*10 per well 5 The cells were seeded in 96-well plates and differentiated into IFN-γ-producing effector cells, referred to as Tc1 cells, under the induction conditions of anti-CD3, anti-CD28, IL-2 and IL-12.

[0117] To the cells prepared above, CKBA compounds (dissolved in DMSO, with the DMSO solvent group without CKBA added as the control) were added in gradient concentrations, with a total volume of 200 μl / well, the control group was added with DMSO of corresponding concentrations, and the blank control group was added with only 200 μl of culture medium, and three replicate wells were set for each group.

[0118] After culturing in a cell culture incubator (37° C., 5% CO 2 ) for 72 hours, the proportion of Tc1 cells was detected by flow cytometry.

[0119] like Figure 1A -C and Table 1, the results show that CKBA compounds can effectively reduce the in vitro differentiation efficiency of Tc1. Compared with the control group with DMSO added, when the added CKBA concentration is 2.5μM, 3μM, 3.5μM, 4μM, 4.5μM, and 5μM, CKBA has a significant inhibitory effect on the differentiation of Tc1 cell subsets; and with the increase of concentration, its inhibitory effect is significantly improved. It can significantly inhibit the production of IFN-γ.

[0120] Table 1

[0121]

[0122]

[0123] Example 2: CKBA compounds inhibit CD8 in vitro + Experiment on inducing differentiation of T cells into Tc17

[0124] 8-10 week old C57BL / 6 mice were selected and red blood cells were lysed with red blood cell lysis buffer to obtain spleen single cell suspension. The mouse naive CD8+ T cell magnetic bead enrichment kit was used to isolate naive CD8+ T cells. + T cells. 1.0*10 per well 5 The cells were seeded in 96-well plates and differentiated into effector cells producing IL-17A, referred to as Tc17 cells, under the induction conditions of anti-CD3, anti-CD28, TGF-β, IL-6, IL-23, IL-1β and anti-IFN-γ. CKBA compounds with gradient concentrations were added at the same time, with a total volume of 200 μl / well. The control group was added with DMSO of corresponding concentrations, and the blank control group was only added with 200 μl of culture medium. Three replicate wells were set for each group.

[0125] After culturing in a cell culture incubator (37° C., 5% CO 2 ) for 72 hours, the proportion of Tc17 cells was detected by flow cytometry.

[0126] like Figure 2A -C and Table 2, the results show that when the CKBA concentration is 0.5 and 1 μM, there is no obvious inhibitory effect on the differentiation of Tc17 cell subpopulations; compared with the control group added with DMSO, when the added CKBA concentration is 1.5, 2, 2.5, 3, 4, 5 μM, CKBA has a significant inhibitory effect on the differentiation of Tc17 cell subpopulations. Thus, IL-17A production can be significantly inhibited.

[0127] Table 2

[0128] Tc17 cell ratio (%) DMSO control 12.83±0.13 1.5 μM CKBA 12.83±0.13 2 μM CKBA 9.84±0.69 2.5 μM CKBA 5.31±1.35 3 μM CKBA 3.05±0.04 4 μM CKBA 2.02±0.55 5 μM CKBA 0.15±0.01

[0129] Example 3. Preparation of ointment and gel containing CKBA

[0130] The inventors unexpectedly discovered during the study that although CKBA can be mixed with different adjuvants to prepare different external dosage forms, the effects of different adjuvants are very significantly different. A properly formulated ointment can significantly promote the effective absorption of CKBA, thereby helping CKBA to exert a better therapeutic effect.

[0131] A certain amount of CKBA compound was taken and prepared into 15 g of ointment according to the formula in Table 3.

[0132] Table 3

[0133]

[0134] White vaseline manufacturer: Nanchang Baiyun Pharmaceutical Co., Ltd.; product batch number: 20221110.

[0135] Light liquid paraffin manufacturer: Nanchang Baiyun Pharmaceutical Co., Ltd.; product batch number: 20210603.

[0136] Meanwhile, a certain amount of CKBA compound was taken to prepare 15 g of gel according to the formula in Table 4.

[0137] Table 4

[0138]

[0139] Example 4: Experiment on the treatment of vitiligo in mice with CKBA ointment

[0140] Twelve 9-week-old C57BL / 6 mice were injected with skin melanoma cells B16F10 on the lower right side of the back, and the melanoma was surgically removed 12 days later. The mice were observed for 30 days after surgery, and the animals whose hair in the surgical area turned white were selected, which successfully established the vitiligo animal model.

[0141] On the 30th day after surgery, 9 mice with vitiligo modeling were selected and divided into 3 groups. They were blank ointment (ointment prepared according to Table 3 but without CKBA), 0.5% CKBA ointment treatment group, and 1.0% CKBA ointment treatment group, with 3 experimental mice in each group. The site of disease was determined, photographed, shaved, and control ointment or CKBA ointment was applied at 15 mg / cm 2 , once a day for 4 consecutive weeks. On the last day, take photos to record the skin and hair color of the drug-administered site, then kill the mice by cervical scissoring, cut the skin of the diseased site, embed the tissue in paraffin, and slice it, and then histochemically stain to detect CD8 + T cells.

[0142] Observe the disease phenotype (the extent of whitening of the back hair and tail) in the animal model, such as Figure 3, the white area in the Vehicle group increased after 28 days of treatment, showing a worsening of the disease. The extent of whitening of the back hair and tail of the animals in the 0.5% CKBA ointment group was significantly reduced after 28 days of treatment (*P<0.05). The extent of whitening of the back hair and tail of the animals in the 1% CKBA ointment group was greatly reduced after 28 days of treatment (**P<0.01). A very significant effect of inhibiting the disease was observed in the animals in the 0.5% CKBA ointment group, and the degree of improvement of the disease in the animals in the 1% CKBA ointment group was better than that in the animals in the 0.5% CKBA ointment group.

[0143] Detection of animal skin infiltrating CD8 + T cell infiltration, the results are as follows Figure 4 It can be seen that after 28 days of treatment, CD8 + The content of T cells was greatly reduced, and the effect was more significant in the 1% CKBA ointment group (**P<0.01).

[0144] The above results indicate that CKBA ointment can effectively improve the phenotype of vitiligo, and its therapeutic effect on vitiligo is surprising.

[0145] Example 5. Comparison of skin permeability of CKBA preparations

[0146] In this example, the in vitro percutaneous permeation characteristics of different types of CKBA preparations (gel or ointment) (Table 5) were analyzed to investigate the percutaneous permeation behavior and skin retention of CKBA when mixed with different excipients.

[0147] Table 5. Samples and reference substances

[0148]

[0149]

[0150] In vitro permeation tests of 0.5% and 1.0% gels and ointments were conducted as follows:

[0151] 1. Source and treatment of ex vivo skin

[0152] The ex vivo skin of the abdomen and back of Bama miniature pigs (half a month old, 1-1.5 kg) was provided by Linxi County Jingde Agricultural Products Sales Co., Ltd. and stored in a -20°C refrigerator for later use.

[0153] Before use, the skin was placed in physiological saline and thawed at room temperature. After checking the integrity of the skin, the moisture on the skin surface was absorbed with absorbent paper, and the skin was cut along the outer edge of the supply pool and placed in physiological saline for later use.

[0154] 2. Transdermal test design and methods

[0155] The in vitro permeation test is designed to simulate the skin permeation process of topical drugs under physiological conditions to reflect the quality of topical preparations and the effectiveness of clinical treatment. The present invention adopts the Franz diffusion cell method and selects pig back skin for in vitro permeation test of CKBA gel and ointment.

[0156] Experimental operation control: The test preparation was prepared in 6 parallel portions.

[0157] 3. Confirmation of in vitro transdermal analysis method for CKBA gel and ointment

[0158] With reference to the two content methods, we tried them separately, selected the better method, and made appropriate adjustments to serve as the chromatographic conditions for in vitro transdermal detection. The details are shown in Table 6.

[0159] Table 6. Comparison of CKBA content analysis methods

[0160]

[0161]

[0162] There was no interference in the blanks of Method 1 and Method 2, and both had normal peaks. Comparing the two methods, Method 1 had a shorter running time and better tailing than Method 2, so this method will be used to detect the transdermal properties of CKBA gel and ointment samples in the future.

[0163] 4. Transdermal test

[0164] (1) Sample preparation

[0165] Mobile phase A: 0.1% phosphoric acid solution. Add 2 ml of phosphoric acid to 2000 ml of pure water, mix well and degas by ultrasonication.

[0166] Mobile phase B: acetonitrile.

[0167] Diluent: 90% methanol solution, measure 900ml of methanol and 100ml of pure water, mix well.

[0168] pH 7.4 PBS buffer: weigh 3.4075 g of potassium dihydrogen phosphate and 0.79419 g of sodium hydroxide into a 500 ml volumetric flask, add water to make up to volume and shake well.

[0169] Receiving solution: pH 7.4 PBS buffer containing 40% PEG400: Measure 157.5 ml of PEG400 into a 500 ml volumetric flask, dilute to the scale with pH 7.4 PBS buffer, and shake well.

[0170] Eluate: Same as diluent.

[0171] Leachate: Same as elution solution.

[0172] Reference solution: Accurately weigh 5.029 mg of SCR-6477 reference substance into a 100 ml volumetric flask, add an appropriate amount of diluent and dissolve it by ultrasonication, then dilute it to the mark with diluent, shake well and mark it as AS-STD#1 solution. Prepare AS-STD#2 solution in the same way, weighing 5.019 mg.

[0173] (2) Drug application and sampling

[0174] A Franz diffusion cell (instrument brand: LOGAN) with a diameter of 1.77 cm and a receiving cell volume of 5 ml was used for the transdermal test. The receiving solution was a pH 7.4 PBS buffer solution containing 40% PEG400.

[0175] Take the abdominal skin of the miniature pig, clean it and rinse it with saline, dry the surface moisture with filter paper, and place it under the donor cavity ring after testing its transepidermal water loss value (TEWL value <15.0). Take an appropriate amount of CKBA gel or ointment and apply it evenly on the stratum corneum skin. The sample amount is about 30 mg. Fix the skin with the sample on the diffusion cell, with the stratum corneum facing up and the dermis facing down. The dissolution cup is filled with degassed receiving solution and placed in a (32±1℃) constant temperature water bath. Turn on the magnetic stirrer at a speed of 350rpm. Take out 4ml of receiving solution in 12h (Note: When measuring the transepidermal water loss value, the measuring environment temperature is: 20 to 25℃; humidity: 30% to 50%RH (non-condensing). Before fixing the skin, the instrument should be turned on in advance to balance the receiving solution in the receiving chamber to 32℃).

[0176] (3) Collection and extraction of remaining samples

[0177] First, after the receiving solution is sampled for 12 hours, the skin is taken out of the transdermal diffusion cell to observe whether there is a clear sample on the skin surface. Two cotton swabs are used to wipe the sample on the skin surface, and the wiped cotton swabs are placed in a 15ml centrifuge tube. 5ml of eluate is taken to rinse the wiped pig skin surface, and the rinsed receiving solution is placed in the above 15ml centrifuge tube; finally, another cotton swab is taken to wipe the remaining eluate on the pig skin surface, and it is also placed in the above 15ml centrifuge tube.

[0178] Secondly, the matrix in the centrifuge tube was dispersed by vortexing with a vortexer, ultrasonicated for 10 minutes, placed in a constant temperature shaker to control the temperature at 32°C, shaken for 4 hours, and centrifuged at 12000 rpm for 5 minutes to obtain the supernatant.

[0179] (4) In vitro skin retention detection

[0180] Cut the cleaned skin into pieces, add 5 ml of the extract, put it into a constant temperature shaker controlled at 32°C, shake it for 4 hours, centrifuge it at 12000 rpm for 5 minutes, and take the supernatant.

[0181] (5) Calculation formula

[0182] a. Cumulative penetration Q

[0183] The cumulative release per unit area per time t is calculated according to the following formula:

[0184] Q=(Cn·V+∑Ci·V) / S

[0185] Q is the cumulative permeation amount per unit area in time t (ng·cm-2), V is the volume of the solution in the receiving pool, Cn is the measured concentration of the nth sample, Ci is the measured concentration of the n-1th sample, and S is the effective permeation area.

[0186] b. Surface sample remaining amount W

[0187] The remaining amount W of the active ingredient in the gel on the skin surface is calculated according to the following formula:

[0188] W=Cs·Vs

[0189] W is the remaining amount of active ingredient in the ointment on the skin surface (ng), Cs is the measured concentration of active ingredient in the ointment on the skin surface, and Vs is the volume of the washout.

[0190] c. Skin retention amount A

[0191] The drug retention amount A in the skin is calculated according to the following formula:

[0192] A=V'Ct

[0193] A is the content of drug per unit mass of skin (ng·g-1), Ct is the concentration measured after skin sample treatment at time t, and V' is the volume of the diluted skin after extraction.

[0194] (6) Experimental results

[0195] The results of the transdermal experiment are shown in Table 7 (statistical average values ​​of multiple batches and multiple animals).

[0196] Table 7. Transdermal test data

[0197]

[0198]

[0199] in conclusion

[0200] The higher the retention in the skin, the better the transdermal effect of the sample. Retention in the skin (μg) 1.0% CKBA ointment > 0.5% CKBA ointment > 1.0% CKBA gel > 0.5% CKBA gel. Surprisingly, the transdermal effect of the prepared ointment preparation is significantly better than that of the gel. No main component was detected in the receiving pool of the four batches of samples.

[0201] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims. At the same time, all the documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference separately.

Claims

1. Use of the compound represented by formula (I) or its isomer, solvate or precursor, or pharmaceutically acceptable salts thereof, for preparing a pharmaceutical composition for alleviating or treating vitiligo; in, R is independently selected from the group consisting of hydrogen, hydroxy, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halogen.

2. The use according to claim 1, characterized in that The pharmaceutical composition containing the compound represented by formula (I) is an external dosage form, including ointments, gels, foams, sprays, powders or creams.

3. The use according to claim 2, characterized in that The pharmaceutical composition is an ointment preparation, comprising: a compound represented by formula (I); and: The auxiliary agent 1 is selected from one or more of white vaseline, paraffin, lanolin, microcrystalline wax, beeswax, spermaceti, ozokerite, glyceryl stearate, stearic acid or cholesterol; preferably, the paraffin is light liquid paraffin; preferably, the auxiliary agent 1 is white vaseline and light liquid paraffin; Auxiliary agent 2 is selected from: one or more of isopropyl myristate, azone or N-methylpyrrolidone; preferably, the auxiliary agent 2 is isopropyl myristate; and The auxiliary agent 3 is selected from one or more of vitamin E, butylated hydroxytoluene, butylated hydroxyanisole, tocopherol, propyl gallate or tert-butylhydroquinone; preferably, the auxiliary agent 3 is vitamin E.

4. The use according to claim 1, characterized in that Described vitiligo is: CD8 + Vitiligo caused by differentiation of T cells into Tc1 cell subsets; and / or CD8 + Vitiligo is caused by T cell differentiation into Tc17 cell subset.

5. A pharmaceutical composition for alleviating or treating vitiligo, comprising: Compound represented by formula (I): wherein R is independently selected from the group consisting of hydrogen, hydroxy, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halogen; and: The auxiliary agent 1 is selected from one or more of white vaseline, paraffin, lanolin, microcrystalline wax, beeswax, spermaceti, ozokerite, glyceryl stearate, stearic acid or cholesterol; preferably, the paraffin is light liquid paraffin; preferably, the auxiliary agent 1 is white vaseline and light liquid paraffin; Auxiliary agent 2 is selected from: one or more of isopropyl myristate, azone or N-methylpyrrolidone; preferably, the auxiliary agent 2 is isopropyl myristate; and The auxiliary agent 3 is selected from one or more of vitamin E, butylated hydroxytoluene, butylated hydroxyanisole, tocopherol, propyl gallate or tert-butylhydroquinone; preferably, the auxiliary agent 3 is vitamin E.

6. The use according to claim 3 or the pharmaceutical composition for alleviating or treating vitiligo according to claim 5, characterized in that: The pharmaceutical composition comprises: a compound represented by formula (I), white vaseline, light liquid paraffin, isopropyl myristate and vitamin E, in parts by weight:

7. Use of the compound represented by formula (I) or its isomer, solvate or precursor, or a pharmaceutically acceptable salt thereof, for preparing a method for inhibiting CD8 + Compositions for T cell differentiation; in, R is independently selected from the group consisting of hydrogen, hydroxy, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halogen; Preferably, the inhibition of CD8 + T cell differentiation: suppressor CD8 + Differentiation of T cells into Tc1; and / or, inhibition of CD8 + Differentiation of T cells into Tc17.

8. A method to inhibit CD8 + A method for differentiating T cells, characterized in that The method comprises: treating CD8 with a compound represented by formula (I) or an isomer, solvate or precursor thereof, or a pharmaceutically acceptable salt thereof; + T cells, thereby inhibiting CD8 + Differentiation of T cells; Preferably, the inhibition of CD8 + T cell differentiation: suppressor CD8 + T cells differentiate into Tc1 subset; and / or, inhibit CD8 + T cells differentiate into the Tc17 subset.

9. The method according to claim 8, characterized in that The compound represented by formula (I) or its isomer, solvate or precursor, or their pharmaceutically acceptable salt is in CD8 + The concentration in T cell culture is 1-100uM; preferably 2-80uM.

10. A method for alleviating or treating vitiligo, characterized in that: The method comprises: administering an effective amount of the pharmaceutical composition of claim 5 or 6 to a subject in need of treatment.

Citation Information

Cited By

  • Vitiligo treatment effect observation through combination of AKBA gel and narrow-spectrum UVB irradiation

    CN121243183A